Rockefeller Capital Management
VVOS icon

Rockefeller Capital Management’s Vivos Therapeutics VVOS Stock Holding History

Rockefeller Capital Management’s Portfolio VVOS Stock Details VVOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-140
Closed -$1K – 3853
2022
Q4 		$1K Hold
140
– – ﹤0.01% 3778
2022
Q3 		$2K Hold
140
– – ﹤0.01% 3636
2022
Q2 		$4K Hold
140
– – ﹤0.01% 3579
2022
Q1 		$9K Hold
140
– – ﹤0.01% 3122
2021
Q4 		$7K Hold
140
– – ﹤0.01% 3165
2021
Q3 		$14K Hold
140
– – ﹤0.01% 2746
2021
Q2 		$17K Hold
140
– – ﹤0.01% 2564
2021
Q1 		$23K Buy
+140
New +$25K ﹤0.01% 2228

Other funds holding VVOS

SWIG
Strategic Wealth Investment Group Louisville, Kentucky $788M AUM 14.6% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BA
Bard Associates Chicago, Illinois $398M AUM 54.32% 1-Year Est. Return
GGI
Godsey & Gibb Inc Richmond, Virginia $1.22B AUM 27.93% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Rockefeller Capital Management's VVOS Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Vivos Therapeutics (VVOS) in Q1 2023, closing a stake of 140 shares — an estimated $1K sold.

Rockefeller Capital Management first reported a position in VVOS in Q1 2021 and held it in 8 quarters. The position peaked at $23K in Q1 2021. 30 funds tracked by Wall St. Rank hold VVOS as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Vivos Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 140 Vivos Therapeutics shares in Q1 2023, an estimated $1K.
  • Rockefeller Capital Management first reported a position in Vivos Therapeutics in Q1 2021 and held it in 8 quarters.
  • Rockefeller Capital Management's Vivos Therapeutics position peaked at $23K in Q1 2021.
  • 30 funds tracked by Wall St. Rank held Vivos Therapeutics as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.